Literature DB >> 984796

Therapeutic effects of ribavirin given by the intraperitoneal or aerosol route against influenza virus infections in mice.

E L Stephen, J W Dominik, J B Moe, J S Walker.   

Abstract

Ribavirin (1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide) is an effective antiviral agent against type A influenza infection of mice. Therapy was most effective when administered as a small-particle aerosol early in the infection. Treatment was also effective by either the intraperitoneal or aerosol route in mice with histological evidence of pneumonia. Ribavirin increased the percent survival, lowered lung virus titers, and decreased the development of lung pathology when therapy was initiated at 6 h as a small-particle aerosol. There was no evidence of pulmonary toxicity or immunosuppressive effects.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 984796      PMCID: PMC429786          DOI: 10.1128/AAC.10.3.549

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Modifications to the Henderson apparatus for studying air-borne infections. Evaluations using aerosols of Listeria monocytogenes.

Authors:  W G ROESSLER; D A KAUTTER
Journal:  J Infect Dis       Date:  1962 Jan-Feb       Impact factor: 5.226

2.  Mechanism of action of anti-influenza benzamidine derivatives.

Authors:  H Fujita; Y Seto; S Toyoshima
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

3.  Responses of mice immunized with influenza virus by serosol and parenteral routes.

Authors:  G H Scott; R J Sydiskis
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

4.  Studies in experimental immunology of influenza. IV. The protective value of active immunization.

Authors:  S FAZEKAS de ST GROTH; M DONNELLEY
Journal:  Aust J Exp Biol Med Sci       Date:  1950-01

5.  Aerosol evaluations of the DeVilbiss No. 40 and Vaponefrin nebulizers.

Authors:  E W Larson; H W Young; J S Walker
Journal:  Appl Environ Microbiol       Date:  1976-01       Impact factor: 4.792

6.  Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice.

Authors:  J S Walker; E L Stephen; R O Spertzel
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

7.  Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides.

Authors:  J T Witkowski; R K Robins; R W Sidwell; L N Simon
Journal:  J Med Chem       Date:  1972-11       Impact factor: 7.446

8.  Influenza virus epidemics: A continuing problem.

Authors:  C G Loosli
Journal:  Geriatrics       Date:  1974-10

9.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

10.  Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals.

Authors:  R W Sidwell; L B Allen; G P Khare; J H Huffman; J T Witkowski; L N Simon; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

View more
  10 in total

1.  Response of influenza virus-infected mice to selected doses of ribavirin administered intraperitoneally or by aerosol.

Authors:  R F Berendt; J S Walker; J W Dominik; E L Stephen
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

Review 2.  Biochemistry and clinical applications of ribavirin.

Authors:  B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

3.  Continuous aerosol therapy system using a modified Collison nebulizer.

Authors:  H W Young; J W Dominik; J S Walker; E W Larson
Journal:  J Clin Microbiol       Date:  1977-02       Impact factor: 5.948

4.  Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers.

Authors:  C R Magnussen; R G Douglas; R F Betts; F K Roth; M P Meagher
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

5.  Effects of small-particle aerosols of rimantadine and ribavirin on arterial blood pH and gas tensions and lung water content of A2 influenza-infected mice.

Authors:  J B Arensman; J W Dominik; D E Hilmas
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

6.  In vivo inhibition of respiratory syncytial virus by ribavirin.

Authors:  J F Hruska; P E Morrow; S C Suffin; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

7.  Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza Type A viruses.

Authors:  W M Shannon; G Arnett; L Westbrook; Y F Shealy; C A O'Dell; R W Brockman
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

8.  Activity of amantadine, rimantadine, and ribavirin against swine influenza in mice and squirrel monkeys.

Authors:  G H Scott; E L Stephen; R F Berendt
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

9.  Effects of ribavirin on respiratory syncytial virus in vitro.

Authors:  J F Hruska; J M Bernstein; R G Douglas; C B Hall
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

Review 10.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.